Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Common Equity: 2019-2025

Historic Common Equity for Lyell Immunopharma (LYEL) over the last 6 years, with Sep 2025 value amounting to $329.1 million.

  • Lyell Immunopharma's Common Equity fell 37.98% to $329.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.1 million, marking a year-over-year decrease of 37.98%. This contributed to the annual value of $382.8 million for FY2024, which is 41.55% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Common Equity stood at $329.1 million, which was up 10.10% from $298.9 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Common Equity registered a high of $1.0 billion during Q2 2021, and its lowest value of -$334.0 million during Q1 2021.
  • Moreover, its 3-year median value for Common Equity was $566.5 million (2024), whereas its average is $538.3 million.
  • In the last 5 years, Lyell Immunopharma's Common Equity skyrocketed by 525.62% in 2021 and then crashed by 47.23% in 2025.
  • Lyell Immunopharma's Common Equity (Quarterly) stood at $929.8 million in 2021, then fell by 10.38% to $833.3 million in 2022, then dropped by 21.40% to $655.0 million in 2023, then crashed by 41.55% to $382.8 million in 2024, then tumbled by 37.98% to $329.1 million in 2025.
  • Its Common Equity was $329.1 million in Q3 2025, compared to $298.9 million in Q2 2025 and $336.5 million in Q1 2025.